Form 4 for TXMD TherapeuticsMD, Inc.
Accepted 2021-12-02 00:00:00 ET · period of report 2021-11-30 · accession 0001209191-21-067391 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-02 | 2021-11-30 | TXMD | Donegan Michael C | CAO, VP of Fin | S - Sale+OE | $0.54 | -29.8K | 99.4K | -23% | -$16.1K |
| D | 2021-12-02 | 2021-11-30 | TXMD | Donegan Michael C | CAO, VP of Fin | M - OptEx | — | +115.0K | 129.2K | +812% | — |
| D | 2021-12-02 | 2021-11-30 | TXMD | Donegan Michael C | CAO, VP of Fin | M - OptEx | $0.00 | -115.0K | 115.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-30 | S | D | 29,790 | $0.54 | 99,368 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $0.4819 to $0.5503 for an average weighted sale price of $0.5353. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2021-11-30 | M | A | 115,000 | — | 129,158 | D | — | — | (F1) On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021. |
| 3 | Derivative | Restricted Stock Units | 2021-11-30 | M | D | 115,000 | $0.00 | 115,000 | D | $0.00 · — to — | 115,000 Common Stock | (F1) On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021. (F4) Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. (F5) The RSUs vest in two equal installments on November 24, 2021 and November 24, 2022. |